The Uganda Virus Research institute (UVRI) in collaboration with Target Malaria Uganda have officially opened a new Arthropod Containment Level 2 (ACL-2) insectary at the UVRI campus, Entebbe.
Target Malaria, is a not-for profit research consortium working with UVRI to develop and share new, cost effective and sustainable genetic technologies to modify mosquitoes and reduce malaria transmission. This new malaria control tool would be complementary to the already existing malaria control tools.
Target Malaria follows a step-wise approach for the development of its research and has as part of this process in collaboration with UVRI built a new and modern insectary at the Uganda Virus Research Institute.
The insectary will be used for future genetically modified mosquito experiments under containment. This will allow the further development of Target Malaria’s activities in Uganda.
The insectary was officially opened by the First Deputy Prime Minister Hon Kirunda Kivejinja also Minister for East African Affairs who represented President Yoweri Museveni.
President Museveni in a speech read by Hon Kiveijinja commended researchers for the continue work on exploring ways to tackle problematic diseases such as Malaria and urged them to continue seeking collaborative efforts to increase the span of their research work.
The Director of Uganda Virus Research Institute Prof Pontiano Kaleebu said the Institute’s aim is to carry out research and discovery for novel vector targeted disease controls. He said the newly opened facility is the first of its kind in the country and will go a long way in enabling research on genetically modified mosquitoes at internationally recommended containment levels.
The Principal Investigator of Target Malaria Dr Jonathan Kayondo said he is extremely excited by the new research and specialised facility which will boost the capacity of scientists researching on malaria.
The insectary opening ceremony was attended by several dignitaries, academia, malaria researchers and other partners in the fight against malaria.